Literature DB >> 10396195

Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis.

K F Tabbara1, S A al-Kharashi.   

Abstract

AIMS: To compare the efficacy of topical nedocromil 2% with fluorometholone 0.1% in vernal keratoconjunctivitis (VKC).
METHODS: In a double masked random design, 24 patients with severe vernal keratoconjunctivitis were placed at random on nedocromil 2% eye drops in one eye and fluorometholone 0.1% in the fellow eye. At the end of the 2 week treatment period, the patient crossed over the eye drops (if asymptomatic in one eye), or continued with nedocromil sodium in both eyes (if asymptomatic in both eyes). All patients were examined weekly and ocular surface temperature recorded for a period of 6 weeks.
RESULTS: Improvement in the watering, discharge, conjunctival hyperaemia, papillary hypertrophy, and Trantas' dots was noted in both groups, but overall fluorometholone was significantly more effective than nedocromil. Eyes treated with fluorometholone showed a significant decrease in ocular surface temperature compared with nedocromil treated eyes (p = 0.03).
CONCLUSIONS: Both nedocromil and fluorometholone were effective in ameliorating the signs and symptoms of vernal keratoconjunctivitis. No adverse effects were noted in the nedocromil group.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396195      PMCID: PMC1722917          DOI: 10.1136/bjo.83.2.180

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

Review 1.  Vernal keratoconjunctivitis.

Authors:  R J Buckley
Journal:  Int Ophthalmol Clin       Date:  1988

2.  Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis.

Authors:  A M Irani; S I Butrus; K F Tabbara; L B Schwartz
Journal:  J Allergy Clin Immunol       Date:  1990-07       Impact factor: 10.793

3.  Ultrastructural analysis of human T and TC mast cells identified by immunoelectron microscopy.

Authors:  S S Craig; N M Schechter; L B Schwartz
Journal:  Lab Invest       Date:  1988-06       Impact factor: 5.662

4.  Two types of human mast cells that have distinct neutral protease compositions.

Authors:  A A Irani; N M Schechter; S S Craig; G DeBlois; L B Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

5.  Adhesion molecules in vernal keratoconjunctivitis.

Authors:  A M Abu el-Asrar; K Geboes; S al-Kharashi; K F Tabbara; L Missotten; V Desmet
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

6.  Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis.

Authors:  M Leino; C Carlson; E Jaanio; T Koivunen; H Lavikkala; K Riihelä; E Takalo
Journal:  Ann Allergy       Date:  1990-04

7.  Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis.

Authors:  M Leino; K Ennevaara; A L Latvala; P Nordgren; A M Posti; R Suves; E Takalo
Journal:  Clin Exp Allergy       Date:  1992-10       Impact factor: 5.018

8.  Topical cyclosporine in vernal keratoconjunctivitis.

Authors:  J H Bleik; K F Tabbara
Journal:  Ophthalmology       Date:  1991-11       Impact factor: 12.079

9.  Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis.

Authors:  S D Trocme; G M Kephart; M R Allansmith; W M Bourne; G J Gleich
Journal:  Am J Ophthalmol       Date:  1989-07-15       Impact factor: 5.258

10.  Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis.

Authors:  M Blumenthal; T Casale; R Dockhorn; I Jarmoszuk; H Kaiser; R Smith; H J Zeitz
Journal:  Am J Ophthalmol       Date:  1992-01-15       Impact factor: 5.258

View more
  5 in total

Review 1.  Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis.

Authors:  F Mantelli; M S Santos; T Petitti; R Sgrulletta; M Cortes; A Lambiase; S Bonini
Journal:  Br J Ophthalmol       Date:  2007-06-22       Impact factor: 4.638

2.  Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis.

Authors:  Fang-Yu Liu; Hsin-Yu Liu; Hsiao-Sang Chu; Wei-Li Chen; Fung-Rong Hu; I-Jong Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-09       Impact factor: 3.117

Review 3.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.

Authors:  A Leonardi; D Bremond-Gignac; M Bortolotti; D Violato; P Pouliquen; L Delval; J M Grouin; I A Fregona
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

Review 5.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.